Genetic Counselor Schindewolf ’14M Interviewed for Research on Rare Disease

February 17, 2015

By James Radke for Rare Disease Report published February 9, 2015

Source: Parents’ Decision Process and Elaprase Treatment

Erica Schindewolf ’14M spoke with weekly newsletter Rare Disease Report about her research on the discontinuation of Elaprase, a prescription drug that improves walking ability in people with Hunter’s disease. Schindewolf, now a genetic counselor at West Virginia University, conducted the research for her thesis project in Arcadia’s Genetic Counseling program and presented it at WORLDSymposium 2015 on Feb. 9.

One of the more interesting poster presentations involves data on the parental perspectives regarding discontinuation of Elaprase (idursulfase) in children with Hunter syndrome, or mucopolysaccharidosis II (MPS II).

Read more

college of health sciencesgenetic counselingplaudits